Statement: The majority of breast cancer patients in the primary trial treated with Lapatinib + Trastuzumab experienced at least Near Complete Pathologic Response, or better, after 12 weeks.
Primary_evidence: Outcome Measurement:    Pathologic Assessment After Study Treatment   Pathologic Assessment After 12 weeks of lapatinib and trastuzumab with or without endocrine therapy. Pathologic complete response: no invasive cancer in the residual breast. Near pathologic complete response: residual disease of less than 1 cm in breast.   Time frame: 12 weeks Results 1:    Arm/Group Title: Lapatinib + Trastuzumab   Arm/Group Description: All study participants received lapatinib 1000mg daily and trauzumab 4mg/kg loading dose and then 2mg/kg every week   Overall Number of Participants Analyzed: 64   Measure Type: Number   Unit of Measure: participants  Complete Pathologic Response: 18   Near Complete Pathologic Response: 16   Not Pathologic response: 30